FDA Approvals in Oncology: July-September 2025
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
From July 1 to September 30, 2025, the FDA issued eight new oncology approvals, expanding treatment options for patients...
In the second quarter of 2025, the FDA issued 13 new oncology approvals, including options for rare cancers, head...
In the first quarter of 2025, the FDA issued 13 approvals for oncology treatments, covering nine types of cancer...
In the final three months of 2024, the FDA issued 15 approvals in oncology, including several therapies that are...
This quarter’s 16 approvals include a first-in-class cell therapeutic, a flurry of new options for EGFR-mutated lung cancer, and...
New cervical cancer self-screening options and a portable blood test device could lead to changes in at-home cancer screening...
The FDA issued 18 oncology-related approvals in Q2 2024 including two first-in-class drugs and a bispecific T-cell engager for...
The FDA issued 14 oncology approvals this quarter, including the first tumor-infiltrating lymphocyte therapy.
Courtney Addison is eternally grateful for the CAR T-cell therapy that sent her son Cayden’s leukemia into remission. But...
With the approval of new anticancer therapeutics, more treatment options become available for patients. Some therapies are new to...